Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.

Author(s): Hasan A, Rothenberger A, Münchau A, Wobrock T, Falkai P, Roessner V

Department of Psychiatry and Psychotherapy, Georg-August-University Göttingen, Göttingen, Germany

Subject: ADD/ADHD View the study

Abstract:

To describe the clinical course of the Delta 9-tetrahydrocannabinol (Delta 9-THC) treatment of a boy with Gilles de la Tourette Syndrome (TS) and comorbid attention-deficit/hyperactivity disorder (ADHD) in relation to Delta 9-THC plasma levels and intracortical inhibition measured by transcranial magnetic stimulation.

Source: Journal of Clinical Psychopharmacology (Price: $49)
Share Tweet

More medical studies related to ADD/ADHD:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

форд киев

www.citroen.niko.ua/

подробно